APLLTD — Alembic Pharmaceuticals Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapHigh Flyer

Annual income statement for Alembic Pharmaceuticals, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2022 March 31st	2023 March 31st	2024 March 31st	2025 March 31st	2026 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	53,058	56,526	62,286	66,721	73,449
Cost of Revenue
Gross Profit	34,618	34,779	40,546	43,555	53,605
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	47,183	52,148	55,679	59,294	66,120
Operating Profit	5,875	4,378	6,607	7,427	7,329
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	6,201	3,546	6,318	7,072	6,940
Provision for Income Taxes
Net Income After Taxes	5,157	3,420	6,158	5,820	6,708
Minority Interest
Equity in Affiliates
Net Income Before Extraordinary Items
Net Income	5,209	3,420	6,158	5,834	6,748
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	5,209	3,420	6,158	5,834	6,748
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	26.5	17.6	31.2	29	37.6
Dividends per Share